arrow
A

Amit S. Kalgutkar

pfizer research & development
H指数:61
被引数:1.5万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Effect of Varying Degrees of Hepatic Impairment on the Pharmacokinetics of Ervogastat, a Diacylglycerol Acyltransferase 2 (DGAT2) Inhibitor, and Clesacostat, an Acetyl-CoA Carboxylase (ACC) Inhibitor

不同程度肝功能损伤对Ervogastat(一种二酰基甘油酰基转移酶2 [DGAT2] 抑制剂)和Clesacostat(一种乙酰辅酶A羧化酶 [ACC] 抑制剂)药代动力学的影响

2025-09-010
PRE
Discovery of First Branched-Chain Ketoacid Dehydrogenase Kinase (BDK) Inhibitor Clinical Candidate PF-07328948
2024-11-190
PRE
Discovery of SARS-CoV-2 papain-like protease (PLpro) inhibitors with efficacy in a murine infection model
2024-08-302
OAAI
A Second-Generation Oral SARS-CoV-2 Main Protease Inhibitor Clinical Candidate for the Treatment of COVID-19
2024-04-3016
OAAI
Discovery of Ervogastat (PF-06865571): A Potent and Selective Inhibitor of Diacylglycerol Acyltransferase 2 for the Treatment of Non-alcoholic Steatohepatitis
2022-11-0214
PRE
A Small-Molecule Oral Agonist of the Human Glucagon-like Peptide-1 Receptor
2022-06-0160
OAAI
Comprehensive Nonclinical Safety Assessment of Nirmatrelvir Supporting Timely Development of the SARS-COV-2 Antiviral Therapeutic, Paxlovid™
2022-05-2114
OA
Practical and Science-Based Strategy for Establishing Acceptable Intakes for Drug Product N-Nitrosamine Impurities

建立药品N-亚硝胺杂质可接受摄入量的实用和科学策略

2022-02-2558
OAAI